October's Legacy: A Nation That Won the War and Mastered the Peace    A Woman's Victory Shakes Global Markets    Egypt's gold reserves expand sharply in Sept, reaching $15.843b    Egypt's PM appoints new heads of Nuclear Regulatory Authority    Egypt's CBE issues EGP 27b T-bonds fixed coupon    Egypt offers 386 ready-to-use industrial units across 11 governorates    BMEC Imaging commits EGP 214.6m to establish cutting-edge medical device manufacturing facility in Ain Sokhna    Egypt reviews Nile water inflows as minister warns of impact of encroachments on Rosetta Branch    Egypt's Al-Sisi commemorates October War, discusses national security with top brass    Egypt launches nationwide medical exams for parliamentary election candidates    Egypt's property exports reach $1.5bn in 2025, marking 200% growth over 2024    EDIC Developments launches DR5 medical center, Celestia gold mall through Egyptian-Saudi partnership    Egypt screens 22.9m women in national breast cancer initiative since July 2019    Egypt's ministry of housing hails Arab Contractors for 5 ENR global project awards    Egypt to host Israeli-Hamas talks on Oct. 6 amid renewed push to end Gaza war    Cairo to host Palestinian conference amid prisoner swap talks, Gaza ceasefire efforts    Sanae Takaichi wins ruling party leadership, set to become Japan's first female PM    China dangles $1trn investment in bid to reset US trade policy: Bloomberg    Saudi German Health Expands Mayo Clinic Partnership, Becomes Region's Largest Member Group    Egypt approves 776,379 state-funded treatment decisions in July–August    Egypt drug regulator, Organon discuss biologics expansion, investment    Egypt's PM addresses parliament on Al-Sisi's objections to criminal procedures bill    A Timeless Canvas: Forever Is Now Returns to the Pyramids of Giza    Egypt aims to reclaim global golf standing with new major tournaments: Omar Hisham    Egypt to host men's, juniors' and ladies' open golf championships in October    Egyptian Writers Conference announces theme for 37th session    Egypt's Al Ismaelia wins heritage award for Downtown Cairo revival    Egypt's Sisi, Uganda's Museveni discuss boosting ties    Egypt's Sisi warns against unilateral Nile measures, reaffirms Egypt's water security stance    Greco-Roman rock-cut tombs unearthed in Egypt's Aswan    Egypt reveals heritage e-training portal    Egypt expands e-ticketing to 110 heritage sites, adds self-service kiosks at Saqqara    Palm Hills Squash Open debuts with 48 international stars, $250,000 prize pool    Germany among EU's priciest labour markets – official data    Paris Olympic gold '24 medals hit record value    A minute of silence for Egyptian sports    Russia says it's in sync with US, China, Pakistan on Taliban    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



GSK says Ebola vaccine development progressing at 'unprecedented rate'
Mega pharmaceutical companies are racing against time in an effort to produce an Ebola vaccine
Reuters Published in Ahram Online on 19 - 10 - 2014

Britain's biggest drugmaker GlaxoSmithKline said on Saturday work to develop a vaccine to combat Ebola, which has killed thousands in West Africa, was moving at a rapid pace.
"Development of the vaccine candidate is progressing at an unprecedented rate, with first phase 1 safety trials with the vaccine candidate underway in the USA, UK and Mali, and further trials due to start in the coming weeks," the firm said in a statement posted on its website.
The company said preliminary data from the trials was expected by the end of 2014 and that, if successful, the next phase, involving the vaccination of frontline healthcare workers in Sierra Leone, Guinea and Liberia, would begin in early 2015.
The worst Ebola outbreak on record has killed more than 4,500 people so far, most in the trio of West African countries. In August, GSK said the experimental vaccine was being fast-tracked into human studies and it planned to build a stockpile of up to 10,000 doses for emergency deployment, if results were good.
The GSK vaccine consists of a common cold virus, called an adenovirus, engineered to carry two genes of the Ebola virus. Animal testing has shown that when the adenovirus infects cells the Ebola genes produce harmless proteins that stimulate the immune system to produce antibodies to Ebola.
GSK acquired the vaccine after buying Swiss-based biotech company Okairos for 250 million euros ($319 million) last year. Responding to public fears after three diagnosed cases in the United States, President Barack Obama urged Americans on Saturday not to give in to "hysteria" about the hemorrhagic fever, which is spread through the blood, sweat or vomit of those infected.
There is no cure or approved vaccine yet for Ebola but several pharmaceutical companies have been working on experimental drugs.
http://english.ahram.org.eg/News/113411.aspx

Clic here to read the story from its source.